(ABBV) AbbVie - Ratings and Ratios
Medicine, Therapy, Cancer Treatment, Autoimmune Disease, Neuroscience
ABBV EPS (Earnings per Share)
ABBV Revenue
Description: ABBV AbbVie
AbbVie Inc. is a research-driven biopharmaceutical company with a diverse portfolio of medicines and therapies across various therapeutic areas, including immunology, oncology, neuroscience, and eye care. The companys flagship product, Humira, is a leading treatment for autoimmune diseases, while newer additions like Skyrizi and Rinvoq are gaining traction in the immunology space. AbbVies oncology portfolio includes Imbruvica, Venclexta/Venclyxto, and Elahere, targeting various blood cancers and solid tumors.
From a financial perspective, AbbVies market capitalization stands at approximately $352 billion, with a forward price-to-earnings ratio of 15.70, indicating a relatively reasonable valuation compared to its expected earnings growth. The companys return on equity (RoE) is exceptionally high at 95.59%, suggesting strong profitability. Key performance indicators (KPIs) to monitor include revenue growth, particularly from newer products, and the companys ability to maintain its pricing power in the face of increasing competition and potential biosimilars.
AbbVies product portfolio is diversified across various therapeutic areas, reducing dependence on a single product. The companys neuroscience franchise, including Vraylar, Duopa, and Duodopa, addresses significant unmet needs in neurology and psychiatry. Additionally, AbbVies eye care portfolio, featuring Ozurdex, Lumigan/Ganfort, and Restasis, provides a stable source of revenue. The recent approval and launch of new products, such as Epkinly and Qulipta, are expected to drive growth and expand the companys addressable market.
To evaluate AbbVies stock, its essential to consider its growth prospects, competitive positioning, and valuation. The companys ability to innovate and bring new products to market, as well as its capacity to navigate the complex landscape of biopharmaceutical pricing and reimbursement, will be crucial in determining its future success. Key metrics to track include AbbVies revenue growth rate, operating margin expansion, and return on invested capital (ROIC).
ABBV Stock Overview
| Market Cap in USD | 351,298m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2013-01-02 |
ABBV Stock Ratings
| Growth Rating | 78.4 |
| Fundamental | 62.3% |
| Dividend Rating | 73.4 |
| Rel. Strength | 21.7 |
| Analysts | 4.00 of 5 |
| Fair Price Momentum | 216.36 USD |
| Fair Price DCF | 178.27 USD |
ABBV Dividends
| Dividend Yield 12m | 3.36% |
| Yield on Cost 5y | 8.36% |
| Annual Growth 5y | 5.61% |
| Payout Consistency | 100.0% |
| Payout Ratio | 61.1% |
ABBV Growth Ratios
| Growth Correlation 3m | 74% |
| Growth Correlation 12m | 16.9% |
| Growth Correlation 5y | 94.4% |
| CAGR 5y | 20.76% |
| CAGR/Max DD 5y | 0.95 |
| Sharpe Ratio 12m | 0.20 |
| Alpha | 1.28 |
| Beta | 0.172 |
| Volatility | 21.40% |
| Current Volume | 4729.3k |
| Average Volume 20d | 4706.3k |
| Stop Loss | 192.6 (-3%) |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (3.77b TTM) > 0 and > 6% of Revenue (6% = 3.50b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 0.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -18.01% (prev -14.73%; Δ -3.29pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 19.28b > Net Income 3.77b (YES >=105%, WARN >=100%) |
| Net Debt (64.01b) to EBITDA (9.94b) ratio: 6.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.77b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 74.26% (prev 62.75%; Δ 11.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.79% (prev 38.75%; Δ 3.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.06 (EBITDA TTM 9.94b / Interest Expense TTM 2.80b) >= 6 (WARN >= 3) |
Altman Z'' -0.59
| (A) -0.08 = (Total Current Assets 29.26b - Total Current Liabilities 39.77b) / Total Assets 137.18b |
| (B) -0.08 = Retained Earnings (Balance) -11.50b / Total Assets 137.18b |
| (C) 0.04 = EBIT TTM 5.75b / Avg Total Assets 139.56b |
| (D) -0.08 = Book Value of Equity -11.50b / Total Liabilities 137.32b |
| Total Rating: -0.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.33
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.39% = 2.20 |
| 3. FCF Margin 31.27% = 7.50 |
| 4. Debt/Equity 21.20 = -2.50 |
| 5. Debt/Ebitda 7.09 = -2.50 |
| 6. ROIC - WACC 5.33% = 6.66 |
| 7. RoE 142.3% = 2.50 |
| 8. Rev. Trend 16.08% = 0.80 |
| 9. Rev. CAGR 1.36% = 0.17 |
| 10. EPS Trend data missing |
| 11. EPS CAGR -37.89% = -2.50 |
As of August 12, 2025, the stock is trading at USD 198.64 with a total of 4,729,301 shares traded.
Over the past week, the price has changed by +0.74%, over one month by +4.11%, over three months by +5.41% and over the past year by +8.19%.
Neither. Based on ValueRay´s Fundamental Analyses, AbbVie is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 62.33 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABBV is around 216.36 USD . This means that ABBV is currently overvalued and has a potential downside of 8.92%.
AbbVie has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ABBV.
- Strong Buy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ABBV AbbVie will be worth about 237 in August 2026. The stock is currently trading at 198.64. This means that the stock has a potential upside of +19.32%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 214.6 | 8% |
| Analysts Target Price | 208.9 | 5.1% |
| ValueRay Target Price | 237 | 19.3% |
ABBV Fundamental Data Overview
CCE Cash And Equivalents = 6.47b USD (Cash only, last quarter)
P/E Trailing = 93.3615
P/E Forward = 16.6389
P/S = 6.0228
P/B = 50.4573
P/EG = 0.4199
Beta = 0.503
Revenue TTM = 58.33b USD
EBIT TTM = 5.75b USD
EBITDA TTM = 9.94b USD
Long Term Debt = 62.96b USD (from longTermDebt, last quarter)
Short Term Debt = 7.52b USD (from shortLongTermDebt, last quarter)
Debt = 70.48b USD (Calculated: Short Term 7.52b + Long Term 62.96b)
Net Debt = 64.01b USD (from netDebt column, last quarter)
Enterprise Value = 415.31b USD (351.30b + Debt 70.48b - CCE 6.47b)
Interest Coverage Ratio = 2.06 (Ebit TTM 5.75b / Interest Expense TTM 2.80b)
FCF Yield = 4.39% (FCF TTM 18.24b / Enterprise Value 415.31b)
FCF Margin = 31.27% (FCF TTM 18.24b / Revenue TTM 58.33b)
Net Margin = 6.46% (Net Income TTM 3.77b / Revenue TTM 58.33b)
Gross Margin = 74.26% ((Revenue TTM 58.33b - Cost of Revenue TTM 15.01b) / Revenue TTM)
[93m Tobins Q-Ratio = -36.10 (set to none) (Enterprise Value 415.31b / Book Value Of Equity -11.50b)
[39m Interest Expense / Debt = 0.96% (Interest Expense 678.0m / Debt 70.48b)
[93m Taxrate = -15.34% (set to none) (from yearly Income Tax Expense: -570.0m / 3.72b)
[39m[93m NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
[39m Current Ratio = 0.74 (Total Current Assets 29.26b / Total Current Liabilities 39.77b)
Debt / Equity = 21.20 (Debt 70.48b / last Fiscal Year total Stockholder Equity 3.33b)
Debt / EBITDA = 7.09 (Net Debt 64.01b / EBITDA 9.94b)
Debt / FCF = 3.86 (Debt 70.48b / FCF TTM 18.24b)
Total Stockholder Equity = 2.65b (last 4 quarters mean)
RoA = 2.75% (Net Income 3.77b, Total Assets 137.18b )
RoE = 142.3% (Net Income TTM 3.77b / Total Stockholder Equity 2.65b)
RoCE = 8.77% (Ebit 5.75b / (Equity 2.65b + L.T.Debt 62.96b))
RoIC = 5.33% (Ebit 5.75b / (Assets 137.18b - Current Assets 29.26b))
[93m WACC = unknown (E(351.30b)/V(421.78b) * Re(6.65%)) + (D(70.48b)/V(421.78b) * Rd(0.96%) * (1-Tc(none)))
[39m Shares Correlation 5-Years: -82.10 | Cagr: -0.09%
Discount Rate = 6.65% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.62% ; FCFE base≈18.06b ; Y1≈17.70b ; Y5≈18.02b
Fair Price DCF = 178.3 (DCF Value 314.93b / Shares Outstanding 1.77b; 5y FCF grow -2.90% → 2.90% )
Revenue Correlation: 16.08 | Revenue CAGR: 1.36%
Revenue Growth Correlation: 92.74%
EPS Correlation: N/A | EPS CAGR: -37.89%
EPS Growth Correlation: -19.48%
Additional Sources for ABBV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle